Why the shares of biotech star Impedimed Limited are rocketing today

The shares of fast-growing biotech company Impedimed Limited (ASX: IPD) rocketed higher by as much as 10% this morning following the release of a positive announcement to the market.

The announcement revealed that a new study published in the Frontiers in Oncology journal demonstrates the impact that the company’s L-Dex lymphoedema detection product can have on patients that are at risk from breast cancer related lymphoedema.

The retrospective study followed 326 patients which had undergone either an axillary lymph node dissection or a sentinel lymph node biopsy with a median follow-up time of 21.7 months. Patients were monitored with L-Dex measurements as part of their routine post-operative follow-up.

The cumulative incidence of sub-clinical lymphoedema was 4.3% for sentinel lymph node biopsy patients and 26.7% for axillary lymph node dissection patients. Very positively L-Dex allowed for early intervention for these patients, which resulted in a reduction of persistent, clinical lymphoedema by 99.5% and 91.4% respectively.

According to the release the study concluded that:

“The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up. This is critically important given the recent changes in the NCCN survivorship guidelines for post-treatment follow-up care for breast cancer patients establishing that health-care providers educate, monitor, and refer for lymphedema management.”

Clearly this is a very positive step forward for L-Dex and it comes as little surprise to see its shares bolt higher. If L-Dex is incorporated into routine breast cancer programs then ImpediMed is in a great position to prosper.

I’m a big fan of ImpediMed and believe that it is up there with the likes of Nanosonics Ltd. (ASX: NAN) and REVA Medical Inc (ASX: RVA) as one of the most promising companies in the sector.

But let’s not forget that it is still early days for both L-Dex and its recently launched health and wellness tracker SOZO. As a result I would suggest restricting any investment in the company to just a small part of your portfolio.

If ImpediMed is a little too high risk for your liking then look no further than these three high quality ASX shares. Each has both growing earnings and fully franked dividends, and could bolt higher in the next few months in my opinion.

Why These 3 Blue Chip Shares Are Set to Soar in 2016

Discover The Motley Fool's Top 3 blue chips for 2016. These 3 'new breed' shares pay fully franked dividends AND offer the prospect of significant capital appreciation. Simply click here to gain access to this comprehensive FREE investment report.

No credit card required!

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.